Form 4: Cadrenal CEO Quang Pham Executes Planned Stock Sale

Cadrenal Therapeutics CEO and Chairman Quang Pham sold 8,285 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Summary

• CEO and Chairman Quang Pham sold a total of 8,285 shares of Cadrenal Therapeutics common stock between June 3, 2026, and June 5, 2026.
• The sales were executed in three tranches at weighted average prices ranging from $4.26 to $4.42 per share.
• Following these transactions, the reporting person directly owns 173,224 shares, with an additional 200,000 shares held indirectly through The PVBQ Living Trust.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while insider selling can be viewed negatively, the use of a pre-planned 10b5-1 arrangement mitigates concerns regarding insider sentiment.

Positives

• The sales were executed under a pre-established Rule 10b5-1 trading plan, which is designed to avoid concerns regarding insider trading by scheduling sales in advance.

Negatives

• The sale of shares by the CEO and Chairman may be perceived by some investors as a lack of confidence in the short-term price appreciation of the stock.

Risks

• Continued selling by major insiders could exert downward pressure on the stock price.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard corporate governance practice for executives to diversify holdings or manage liquidity without triggering market concerns regarding non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives at publicly traded biotech firms to conduct orderly divestments.
• The volume of shares sold represents a small fraction of the CEO's total beneficial ownership, which is consistent with typical executive diversification strategies.

Related Party Transactions

• The reporting person maintains indirect ownership through The PVBQ Living Trust, where the reporting person serves as Trustee.

Stakeholder Impact

• Shareholders should note the ongoing divestment activity, though the volume is limited relative to total holdings.

Next Steps

• Continued monitoring of future Form 4 filings to track further insider activity.

Key Dates

Recommendation

The filing represents routine insider selling under a pre-planned arrangement and does not signal a fundamental change in the company's business outlook or financial health.

Keywords

Cadrenal Therapeutics, CVKD, Insider Trading, Form 4, Quang Pham, Rule 10b5-1